SCHEMBL4900779

SCHEMBL4900779

Cc1ccc(-c2cccc(-c3nc4ccc(Cl)cc4[nH]3)n2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.57
METAP1 P53582 4/20 0.57
CBFB Q13951 2/20 0.57
ADORA3 P0DMS8 1/20 0.55
NPC1 O15118 2/20 0.50
PKM P14618 1/20 0.50
RAB9A P51151 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TP53 P04637 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
FTO Q9C0B1 1/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902859 0.77 ADORA3 (0.63) METAP2METAP1CBFBADORA3NPC1
SCHEMBL8025640 0.73 CCR1 (0.73) METAP2RAB9AMEN1KMT2AALDH1A1
SCHEMBL4183736 0.73 CBFB (0.81) METAP2METAP1CBFBADORA3NPC1
SCHEMBL11460146 0.73 NPC1 (0.61) METAP2METAP1CBFBADORA3NPC1
SCHEMBL18973805 0.73 METAP2 (0.60) METAP2METAP1CBFBNPC1PKM
SCHEMBL4806610 0.72 CBFB (0.55) METAP2METAP1CBFBADORA3NPC1
SCHEMBL4811396 0.72 CBFB (0.67) METAP2METAP1CBFBADORA3NPC1
SCHEMBL21976942 0.72 METAP2 (0.67) METAP2METAP1CBFBNPC1PKM
SCHEMBL27819180 0.71 ALDH1A1 (0.63) METAP2METAP1CBFBADORA3NPC1
SCHEMBL35032 0.71 CBFB (0.50) METAP2METAP1CBFBADORA3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators ICAGEN, INC. (US) 2008-05-08 US disclosed
EP-1737852-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS Icagen, Inc. (US) 2007-01-03 EP disclosed
WO-2005100349-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN, INC. (US) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators KCNJ2, KCNH2, KCNQ1 METAP2 4135/4885METAP1 4396/4885CBFB 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.